Standard Biotools Inc. (LAB): Cost of Revenue
$42.79M
Year ended 2025-12-31
$41.89M
Trailing 12 months to 2026-06-30
-11.1%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.79M | -7.2% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $46.12M | -17.5% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $55.89M | -8.2% | 2026-03-16, From 2023-01-01 |
| 2022-12-31 | $60.90M | n/a | 2025-03-11, From 2022-01-01 |
| No annual figure between 2019-12-31 and 2022-12-31. | |||
| 2019-12-31 | $52.96M | +3.2% | 2020-02-27, From 2019-01-01 |
| 2018-12-31 | $51.31M | +2.7% | 2020-02-27, From 2018-01-01 |
| 2017-12-31 | $49.95M | +8.6% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $46.01M | n/a | 2019-03-18, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Standard Biotools Inc. (LAB) | 2025-12-31 | $42.79M | -7.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $5.80M | -2.5% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $37.21M | +138.5% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $29.70M | -5.1% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $57.56M | -31.5% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $12.45M | +40.2% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $20.92M | +0.2% |
| Nuvation Bio Inc. (NUVB) | 2024-12-31 | $7.08M | n/a |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $5.42M | +39.4% |
Compare LAB, ADCT, ETON, SIGA side by side · Screen every company in Pharmaceutical Preparations ↗